Press "Enter" to skip to content

AstraZeneca’s blood cancer drug meets main goal in late-stage trial

The drug, Calquence, showed meaningful improvement in patients with lymphocytic leukaemia when compared with a chemotherapy-based treatment, the company said.

Original source: https://health.economictimes.indiatimes.com/news/pharma/astrazenecas-blood-cancer-drug-meets-main-goal-in-late-stage-trial/69672918?utm_source=RSS&utm_medium=ETRSS

Also Read:   Alembic gets USFDA nod for generic glaucoma drug